Dihydroergotamine nasal and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Dihydroergotamine nasal and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dihydroergotamine
Brand name: DHE. 45, Migranal
Synonyms: Dihydroergotamine (injection), Dihydroergotamine
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dihydroergotamine nasal-Insulin degludec
- Dihydroergotamine nasal-Insulin Degludec (U-100) Prefilled Pens
- Dihydroergotamine nasal-Insulin Degludec (U-100) Vials
- Dihydroergotamine nasal-Insulin Degludec (U-200) Prefilled Pens
- Dihydroergotamine nasal-Insulin degludec and liraglutide
- Dihydroergotamine nasal-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Dihydroergotamine Nasal Spray
- Insulin aspart, recombinant Subcutaneous-Dilacor XR
- Insulin aspart, recombinant Subcutaneous-Dilantin
- Insulin aspart, recombinant Subcutaneous-Dilantin Infatabs
- Insulin aspart, recombinant Subcutaneous-Dilantin injection
- Insulin aspart, recombinant Subcutaneous-Dilantin Kapseals